Search our Database of Scientific Publications and Authors

I’m looking for a

    978 results match your criteria Nephrogenic Systemic Fibrosis

    1 OF 20

    Gadolinium-based contrast agents induce gadolinium deposits in cerebral vessel walls, while the neuropil is not affected: an autopsy study.
    Acta Neuropathol 2018 May 10. Epub 2018 May 10.
    Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 30, 48149, Münster, Germany.
    Recent studies showed gadolinium depositions following serial administrations of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging examinations in various parts of the brain with the dentate nucleus (DN) being most affected. Even though no clinical correlates of the deposits are known yet, an intensive debate developed if this might be harmful. The aim of the current study was to specify the gadolinium distribution in brain tissue of patients who received serial injections of GBCAs in the low-µm range and to explore any potential pathological tissue changes caused by gadolinium deposits. Read More

    Sources, behaviour, and environmental and human health risks of high-technology rare earth elements as emerging contaminants.
    Sci Total Environ 2018 Apr 26;636:299-313. Epub 2018 Apr 26.
    Marine Biology Institute, Shantou University, Shantou, Guangdong Province, China 515063.
    Recent studies show that high-technology rare earth elements (REEs) of anthropogenic origin occur in the environment including in aquatic systems, suggesting REEs are contaminants of emerging concern. However, compared to organic contaminants, there is a lack of comprehensive reviews on the anthropogenic sources, environmental behaviour, and public and ecological health risks of REEs. The current review aims to: (1) identify anthropogenic sources, transfer mechanisms, and environmental behaviour of REEs; (2) highlight the human and ecological health risks of REEs and propose mitigation measures; and (3) identify knowledge gaps and future research directions. Read More

    Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
    Can Assoc Radiol J 2018 May;69(2):136-150
    Division of Nephrology, Department of Medicine and Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
    Use of gadolinium-based contrast agents (GBCAs) in renal impairment is controversial, with physician and patient apprehension in acute kidney injury (AKI), chronic kidney disease (CKD), and dialysis because of concerns regarding nephrogenic systemic fibrosis (NSF). The position that GBCAs are absolutely contraindicated in AKI, CKD stage 4 or 5 (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m) and dialysis-dependent patients is outdated, and may limit access to clinically necessary contrast-enhanced MRI examinations. Read More

    Methodological Aspects for Preclinical Evaluation of Gadolinium Presence in Brain Tissue: Critical Appraisal and Suggestions for Harmonization-A Joint Initiative.
    Invest Radiol 2018 Apr 13. Epub 2018 Apr 13.
    Gadolinium (Gd)-based contrast agents (GBCAs) are pharmaceuticals that have been approved for 30 years and used daily in millions of patients worldwide. Their clinical benefits are indisputable. Recently, unexpected long-term presence of Gd in the brain has been reported by numerous retrospective clinical studies and confirmed in preclinical models particularly after linear GBCA (L-GBCA) compared with macrocyclic GBCA (M-GBCA). Read More

    10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.
    Invest Radiol 2018 Mar 16. Epub 2018 Mar 16.
    Objectives: The aim of this study was to critically assess the evaluation and categorization process for nephrogenic systemic fibrosis (NSF) based on reports received by Bayer from 2006 to 2016.

    Materials And Methods: A total of 779 NSF reports received by Bayer globally from 2006 to 2016 were included in the analysis. Arlington Medical Resources provided gadolinium-based contrast agent (GBCA) market share. Read More

    An assessment of exposure to rare earth elements among patients receiving long-term parenteral nutrition.
    J Trace Elem Med Biol 2018 May 12;47:156-163. Epub 2018 Feb 12.
    Laboratory of Inorganic and Nuclear Chemistry, Division of Environmental Health Sciences, Wadsworth, Center, New York State, Department of Health, Albany, NY, 12201-0509, United States; Department of Environmental Health Sciences, School of Public Health, The University at Albany, State University of New York, Albany, NY, 12201-0509, United States. Electronic address:
    Patients receiving long-term parenteral nutrition (PN) are exposed to potentially toxic elements, which may accumulate in bone. Bone samples collected from seven PN patients (average = 14 years) and eighteen hip/knee samples were analyzed for Al as part of a previous investigation. Yttrium was serendipitously detected in the PN bone samples, leading to the present investigation of rare earth elements (REEs). Read More

    Gadolinium-Based Contrast Agent-Related Toxicities.
    CNS Drugs 2018 Mar;32(3):229-240
    Neuroradiology Unit, Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy.
    In recent years, gadolinium-based contrast agents have been associated with different types of toxicity. In particular, nephrogenic systemic fibrosis, a progressive sclerotic-myxedematous systemic disease of unknown etiology, is related to gadolinium-based contrast agent administration in patients with kidney dysfunction. More recently, evidence of magnetic resonance signal intensity changes on pre-contrast T1-weighted images after multiple gadolinium-based contrast agent administrations resulted in the hypothesis of gadolinium brain accumulation in patients with normal renal function, subsequently confirmed in pathological samples. Read More

    Gadolinium as a new emerging contaminant of aquatic environments.
    Environ Toxicol Chem 2018 Feb 23. Epub 2018 Feb 23.
    Department of Environmental Toxicology, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.
    Since the 1980s, gadolinium (Gd)-based contrast agents (GBCAs) have been routinely used in magnetic resonance imaging as stable chelates of the Gd ion, without toxic effects. Generally, GBCAs are considered some of the safest contrast agents. However, it has been observed that they can accumulate in patient tissue, bone, and probably brain (causing nephrogenic systemic fibrosis in patients with kidney failure or insufficiency and disturbance of calcium homeostasis in the organism). Read More

    Is it safe to use gadolinium-based contrast agents in MRI?
    J R Coll Physicians Edinb 2017 Sep;47(3):243-246
    R Pullicino, Neuroradiology Department, The Walton Centre NHS, Foundation Trust, Lower Lane, Liverpool L9 7LJ, UK. Email:
    Gadolinium-based contrast agents have greatly expanded the capability of magnetic resonance imaging and have been used extensively in neuroradiology over the past 30 years. When initially developed they were thought to be relatively harmless; it was later discovered they are associated with nephrogenic systemic fibrosis and should be used with caution in certain patient groups, especially those with renal failure. Lately it has been found that the use of these contrast agents may result in deposition of gadolinium in the brain even in patients with an intact blood-brain barrier. Read More

    Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease.
    Kidney Blood Press Res 2018 8;43(1):134-142. Epub 2018 Feb 8.
    1st Department of Pediatrics, Semmelweis University, Budapest, Hungary.
    Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious effects on the cardiovascular (CV) system are already at work. Thus, the assessment of early CV damage is of crucial importance in preventing major CV events. Myocardial fibrosis is one of the major consequences of progressive CKD, as it may lead to reentry arrhythmias and long-term myocardial dysfunction predisposing to sudden death and/or congestive heart failure. Read More

    Scleroderma with an update about clinico-pathological correlation.
    G Ital Dermatol Venereol 2018 Apr 24;153(2):208-215. Epub 2018 Jan 24.
    Department of Molecular Medicine, "Sapienza" University, Rome, Italy.
    Scleroderma is divided into a systemic form called systemic sclerosis and a localized form also called morphea. According to 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis, developed by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), skin thickening of the fingers extending proximal to the metacarpophalangeal joints is sufficient for a patient to be classified as having scleroderma. Histological examination is not included in the diagnostic criteria and is not routinely performed. Read More

    Science to Practice: Will Gadolinium Chelates Be Replaced by Iron Chelates in MR Imaging?
    Radiology 2018 02;286(2):409-411
    Stefanie Spielman Professor Department of Radiology Wright Center for Innovation in Biomedical Imaging The Ohio State University Biomedical Research Tower BR 720, 460 W 12th Ave Columbus, OH 43210.
    Boehm-Sturm et al ( 1 ) pose a possible paradigm shift in magnetic resonance (MR) imaging: the substitution of iron chelates for gadolinium chelates as paramagnetic contrast agents. The advent of nephrogenic systemic fibrosis challenges the wide-spread perception that gadolinium is benign, and that all gadolinium-based contrast agents (GBCAs) are identical. Long-term gadolinium retention in patients with normal renal function is now a disturbing fact. Read More

    Notice of Withdrawal: MR Imaging and Gadolinium: Reassessing the Risk of Nephrogenic Systemic Fibrosis in Patients with Severe Renal Disease.
    Radiology 2018 01;286(1):120-121
    From the Department of Radiology, Weill Cornell Medicine, 416 E 55th St, New York, NY 10022 (M.R.P.); Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY (M.R.P.); and Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Conn (J.C.W.).
    This editorial has been withdrawn from publication by the authors in conjunction with the withdrawal of the highlighted manuscript (see Read More

    [Nephrogenic fibrosing dermatosis: From clinic to microscopy].
    Nephrol Ther 2018 Feb 26;14(1):47-49. Epub 2017 Nov 26.
    Département d'anatomie et de cytologie pathologique, hôpital Charles-Nicolles, université El-Manar, 1006 Tunis, Tunisie.
    Nephrogenic systemic fibrosis is a rare entity occurred in patients with renal failure. It is related to toxicity to gadolinium, which is used as a contrast agent in magnetic resonance imaging. Clinic manifestations are variable. Read More

    Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies.
    Radiologia 2017 Nov - Dec;59(6):469-477. Epub 2017 Oct 27.
    Servicio de Farmacia, Hospital General Universitario de Valencia, Valencia, España.
    The Spanish Agency for Drugs and Healthcare Products (AEMPS), based on the recommendations of the European Committee for Risk Assessment in Pharmacovigilance, established on 13 March 2017 that linear gadolinium-based MR contrast media, such as MultiHance, Omniscan, Magnevist (currently not marketed) and Optimark (no longer marketed in Spain), the clinical benefits do not outweigh the potential risks derived from their use. AEMPS recommends to suspend its marketing for general use based on the retention of these compounds in the brain. On the other hand, the AEMPS justifies the maintenance of Primovist and MultiHance for liver studies, and Magnevist of intra-articular administration (not commercialized in Spain), and justified the almost exclusive use of macrocyclic structure contrasts (Gadovist, ProHance and Dotarem). Read More

    Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.
    Philos Trans A Math Phys Eng Sci 2017 Nov;375(2107)
    Department of Biomedical Engineering, University of California, Davis, CA 95616, USA
    No discussion of challenges for chemistry in molecular imaging would be complete without addressing the elephant in the room-which is that the purest of chemical compounds needs to interact with a biological system in a manner that does not perturb normal biology while still providing efficacious feedback to assist in diagnosis of disease. In the past decade, magnetic resonance imaging (MRI) agents long considered inert have produced adverse effects in certain patient populations under certain treatment regimens. More recently, inert blood pool agents have been found to deposit in the brain. Read More

    A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.
    BMJ Case Rep 2017 Oct 11;2017. Epub 2017 Oct 11.
    Department of Internal Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA.
    A 57-year-old woman presented with swelling and thickening of the skin of the lower extremities. Three months prior to presentation, patient had MRI with gadolinium as part of an evaluation for suspected pancreatic malignancy. Creatinine levels at the time of gadolinium exposure were 0. Read More

    Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
    Radiography (Lond) 2017 Nov 11;23(4):e108-e113. Epub 2017 May 11.
    Department of Imaging Technology & Sonography, University of Cape Coast, Cape Coast, Central Region, Ghana. Electronic address:
    Introduction: The aim of this study is to identify current practice of administration of gadolinium-based contrast agents (GBCAs) in Ghana.

    Method: A total of 13 MRI (magnetic resonance imaging) facilities were sent a survey questionnaire to request information on their current practice with the use of GBCAs.

    Results: Gadodiamide, a high risk GBCA accounted for 67% of first line agents. Read More

    Safety of Contrast Material Use in Children.
    Magn Reson Imaging Clin N Am 2017 Nov 8;25(4):779-785. Epub 2017 Sep 8.
    Division of Pediatric Radiology and Pediatric Neuroradiology, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 1800 Orleans Street, Zayed Tower, Room 4174, Baltimore, MD 21287, USA.
    Iodinated and gadolinium-based contrast materials have excellent safety profiles for use in pediatric computed tomography and MR imaging. The rate of acute adverse reactions and contrast-induced nephropathy is lower than in adults. The relationship between nephrogenic systemic fibrosis and gadolinium administration is well established and only a small number of children suffer from this debilitating disorder. Read More

    Historical Perspective of Imaging Contrast Agents.
    Magn Reson Imaging Clin N Am 2017 Nov 23;25(4):685-696. Epub 2017 Aug 23.
    Department of Radiology, University of North Carolina School of Medicine, 3326 Old Infirmary, Campus Box 7510, Chapel Hill, NC 27599-7510, USA.
    Contrast agents were introduced early in the history of medical imaging. Iodine-based intravascular agents became the radiographic compounds of choice and refinements of their chemical structures led to the highly tolerated low-osmolarity agents in use today. Gadolinium became the most popular compound for MR imaging; however, recognition of nephrogenic systemic fibrosis and in vivo dechelation intensified research on their safety profile. Read More

    Metabolomic Analysis of N-acetylcysteine Protection of Injury from Gadolinium-DTPA Contrast Agent in Rats with Chronic Renal Failure.
    OMICS 2017 Sep;21(9):540-549
    1 Changchun Institute of Applied Chemistry , Chinese Academy of Sciences, Changchun, People's Republic of China .
    Gadolinium-based contrast agents (GBCAs) are frequently used to enhance the diagnostic efficacy of magnetic resonance imaging. On the other hand, the association between GBCA administration in patients with advanced renal disease and nephrogenic systemic fibrosis (NSF) was also noted. NSF is a systemic disorder characterized by widespread tissue fibrosis that may lead to death. Read More

    GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Radiol Technol 2017 Jul;88(6):583-589
    Purpose: To examine the risks of using of gadolinium-based contrast agents (GBCAs) in magnetic resonance (MR) imaging and explore strategies to reduce the likeliness of adverse effects in patients who might be at risk for developing nephrogenic system fibrosis (NSF).

    Methods: A search of 3 scholarly databases was performed to identify articles that discuss adverse reactions to GBCAs, specifically relating to kidney function, in MR examinations. A total of 20 peer-reviewed articles were analyzed. Read More

    Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients.
    Oncotarget 2017 Aug 27;8(32):53542-53551. Epub 2017 Jun 27.
    Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
    Summarizing The Importance Of The Study: The repetitive usage of gadolinium-based contrast agents (GBCA) is critical for magnetic resonance imaging (MRI) evaluation of tumor burden in glioblastoma patients. It is also a crucial tool for determination of radiographical response to treatment. GBCA injection, however, comes with a 2. Read More

    Pathophysiological Mechanisms in Sclerosing Skin Diseases.
    Front Med (Lausanne) 2017 18;4:120. Epub 2017 Aug 18.
    Department of Dermatology, University of Cologne, Cologne, Germany.
    Sclerosing skin diseases represent a large number of distinct disease entities, which include systemic sclerosis, localized scleroderma, and scleredema adultorum. These pathologies have a common clinical appearance and share histological features. However, the specific interplay between cytokines and growth factors, which activate different mesenchymal cell populations and production of different extracellular matrix components, determines the biomechanical properties of the skin and the clinical features of each disease. Read More

    Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
    Methods Mol Biol 2017 ;1627:1-23
    The Joan and Joel Rosenbloom Center for Fibrotic Diseases and The Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
    Human fibrotic diseases constitute a major health problem worldwide owing to the large number of affected individuals, the incomplete knowledge of the fibrotic process pathogenesis, the marked heterogeneity in their etiology and clinical manifestations, the absence of appropriate and fully validated biomarkers, and, most importantly, the current void of effective disease-modifying therapeutic agents. The fibrotic disorders encompass a wide spectrum of clinical entities including systemic fibrotic diseases such as systemic sclerosis (SSc), sclerodermatous graft vs. host disease, and nephrogenic systemic fibrosis, as well as numerous organ-specific disorders including radiation-induced fibrosis and cardiac, pulmonary, liver, and kidney fibrosis. Read More

    European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.
    J Eur Acad Dermatol Venereol 2017 Oct 8;31(10):1581-1594. Epub 2017 Aug 8.
    Department of Dermatology and Venereology, University Hospital of Cologne, Cologne, Germany.
    The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. Read More

    Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function.
    Indian J Radiol Imaging 2017 Apr-Jun;27(2):141-147
    Department of Radio-diagnosis, VMMC and Safdarjung Hospital, New Delhi, India.
    Despite being decked as the most prized compounds in the nugget box of contrast agents for clinical radiologists, and carrying an indisputable tag of safety of the US Food and Drug Administration for close to three decades, all may not be seemingly well with the family of gadolinium compounds. If the first signs of violations of in relation to gadolinium-based contrast agents (GBCAs) appeared in the millennium year with the first published report of skin fibrosis in patients with compromised renal function, the causal relationship between the development of nephrogenic systemic fibrosis (NSF) and GBCAs, first proposed by two European groups in 2006, further precluded their use in renocompromised patients. The toxicity, pharmacokinetics, and pharmacodynamics of GBCAs, however, has come under hawk-eyed scrutiny with recent reports that gadolinium tends to deposit cumulatively in the brain of patients with normal hepatobiliary function and intact blood-brain barrier. Read More

    Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation.
    BMC Nephrol 2017 Jul 24;18(1):249. Epub 2017 Jul 24.
    Unit of Nephrology, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
    Background: Nephrogenic systemic fibrosis (NSF) is a complication of the gadolinium-based contrast agent used in imaging studies. It is typically characterised by hard, erythematous and indurated skin plaques with surrounding subcutaneous oedema. Distinct papules and subcutaneous nodules can also be seen. Read More

    Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease.
    Radiology 2018 01 21;286(1):113-119. Epub 2017 Jul 21.
    From the Department of Medical Imaging, University of Arizona College of Medicine, Banner University Medical Center, 1501 N Campbell Ave, PO Box 245067 Tucson, AZ 85724 (D.R.M., B.K., K.S., S.V.); and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (A.M., P.K.M.).
    The authors have requested to withdraw this manuscript from publication because the study was not conducted in full accordance with the relevant institutional IRB protocol. RSNA, 2018. Read More

    Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
    Clin Rev Allergy Immunol 2017 Dec;53(3):306-336
    Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
    Scleroderma refers to an autoimmune connective tissue fibrosing disease, including three different subsets: localized scleroderma, limited cutaneous systemic sclerosis, and diffuse cutaneous systemic sclerosis with divergent patterns of organ involvement, autoantibody profiles, management, and prognostic implications. Although systemic sclerosis is considered the disease prototype that causes cutaneous sclerosis, there are many other conditions that can mimic and be confused with SSc. They can be classified into immune-mediated/inflammatory, immune-mediated/inflammatory with abnormal deposit (mucinoses), genetic, drug-induced and toxic, metabolic, panniculitis/vascular, and (para)neoplastic disorders according to clinico-pathological and pathogenetic correlations. Read More

    Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis.
    Case Rep Dermatol Med 2017 12;2017:3240287. Epub 2017 Jun 12.
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA.
    Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is a rare complication of exposure to gadolinium-based contrast agents in patients who have significantly decreased renal function. Manifestations include fibrosis of the skin and other tissues. Effective therapies are lacking. Read More

    Non-enhanced versus low-dose contrast-enhanced renal magnetic resonance angiography at 7 T: a feasibility study.
    Acta Radiol 2018 Mar 10;59(3):296-304. Epub 2017 Jul 10.
    1 Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
    Background Considering the currently reported association between a repetitive application and cumulative dosage of Gadolinium (Gd)-based contrast agents and Gd-deposition in brain tissue as well as the risk for the advent of nephrogenic systemic fibrosis (NSF), techniques allowing for a dose reduction become an important key aspect aside from non-enhanced magnetic resonance angiography (MRA) techniques. Thus, this study was focused on the reduction and/or complete omission of contrast agent for renal MRA at 7T. Purpose To evaluate the performance of time-of-flight MRA versus low-dose contrast-enhanced (CE) renal MRA at 7T. Read More

    Nephrogenic systemic fibrosis.
    Clin Case Rep 2017 Jul 16;5(7):1184-1185. Epub 2017 May 16.
    Division of Nephrology, Hypertension and Renal TransplantationUniversity of FloridaGainesvilleFlorida.
    Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder seen in patients with renal dysfunction, commonly precipitated by administration of gadolinium contrast. There is no consistently successful treatment, but oral steroids, topical dovonex, extracorporeal photopheresis, and plasmapheresis have been tried [http://www.icnfdr. Read More

    Scleroderma-like Disorders.
    Curr Rheumatol Rev 2018 Apr;14(1):22-27
    Fortis Escorts Hospital, Jaipur, Rajasthan, India.
    Background: Scleroderma is a term used to describe diseases that involve hardening and tightening of the skin and the underlying subcutaneous connective tissue. It could be localized to skin and subcutaneous tissue, or may involve the internal organs too in systemic sclerosis.

    Objective: There are disorders that can cause hardening and tightening of skin and mimic scleroderma but are rarely associated with Raynaud phenomenon, sclerodactyly, and autoantibodies in the serum, features specific to scleroderma/systemic sclerosis. Read More

    Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedside.
    Cardiovasc Diagn Ther 2017 Apr;7(2):159-170
    Department of Cardiovascular Imaging, Diagnóstico Maipú, Buenos Aires, Argentina.
    A large number of studies support the increasingly relevant prognostic value of the presence and extent of delayed enhancement (DE), a surrogate marker of fibrosis, in diverse etiologies. Gadolinium and iodinated based contrast agents share similar kinetics, thus leading to comparable myocardial characterization with cardiac magnetic resonance (CMR) and cardiac computed tomography (CT) at both first-pass perfusion and DE imaging. We review the available evidence of DE imaging for the assessment of myocardial infarction (MI) using cardiac CT (CTDE), from animal to clinical studies, and from 16-slice CT to dual-energy CT systems (DECT). Read More

    The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.
    Adv Chronic Kidney Dis 2017 05;24(3):176-182
    Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC.
    The role of gadolinium (Gd)-based contrast agents (GBCAs) in the pathophysiology of nephrogenic systemic fibrosis (NSF) is now uncontested. Although the definitive mechanism has not been established, the association with weaker GBCA ligands and with reduced renal clearance supports a hypothesis that Gd release from the GBCAs is a key process in precipitating the disease. Prevention strategies often include the use of more stable GBCA ligands in patients with reduced kidney function, but animal models and some clinical data suggest that better patient outcomes can be achieved when excess ligand is administered with weaker GBCAs; this is particularly significant for OptiMARK, which contains a nonionic, linear ligand similar to gadodiamide, the active ingredient in Omniscan, but contains twice the amount of excess ligand. Read More

    Gadolinium Retention and Toxicity-An Update.
    Adv Chronic Kidney Dis 2017 05;24(3):138-146
    Department of Radiology, Hospital Garcia de Orta, Almada, Portugal; Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC; and Department of Radiology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal. Electronic address:
    Until 2006, the main considerations regarding safety for all gadolinium-based contrast agents (GBCAs) were related to short-term adverse reactions. However, the administration of certain "high-risk" GBCAs to patients with renal failure resulted in multiple reported cases of nephrogenic systemic fibrosis. Findings have been reported regarding gadolinium deposition within the body and various reports of patients who report suffering from acute and chronic symptoms secondary to GBCA's exposure. Read More

    Scleroderma Mimickers.
    Curr Treatm Opt Rheumatol 2016 Mar 5;2(1):69-84. Epub 2016 Feb 5.
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    Cutaneous fibrosing disorders encompass a diverse array of diseases united by the presence of varying degrees of dermal sclerosis. The quality and distribution of skin involvement, presence or absence of systemic complications and unique associated laboratory abnormalities often help to distinguish between these diseases. It is imperative that an effort is made to accurately differentiate between scleroderma and its mimics, in order to guide long-term management and facilitate implementation of the appropriate treatment modality where indicated. Read More

    Appropriate Minimal Dose of Gadobutrol for 3D Time-Resolved MRA of the Supra-Aortic Arteries: Comparison with Conventional Single-Phase High-Resolution 3D Contrast-Enhanced MRA.
    AJNR Am J Neuroradiol 2017 Jul 4;38(7):1383-1390. Epub 2017 May 4.
    Department of Radiology (H.S.A.), Armed Forces Yangju Hospital, Yangju, Korea.
    Background And Purpose: The development of nephrogenic systemic fibrosis and neural tissue deposition is gadolinium dose-dependent. The purpose of this study was to determine the appropriate minimal dose of gadobutrol with time-resolved MRA to assess supra-aortic arterial stenosis with contrast-enhanced MRA as a reference standard.

    Materials And Methods: Four hundred sixty-two consecutive patients underwent both standard-dose contrast-enhanced MRA and low-dose time-resolved MRA and were classified into 3 groups; group A (a constant dose of 1 mL for time-resolved MRA), group B (2 mL), or group C (3 mL). Read More

    Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-induced protoporphyrin IX for high-grade gliomas.
    Oncol Lett 2017 Mar 27;13(3):1269-1275. Epub 2016 Dec 27.
    Department of Neurosurgery, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807-8555, Japan.
    Magnetic resonance imaging (MRI) with a gadolinium-based contrast agent is the gold standard for high-grade gliomas (HGGs). The compound 5-aminolevulinic acid (5-ALA) undergoes a high rate of cellular uptake, particularly in cancer cells. In addition, fluorescence-guided resection with 5-ALA is widely used for imaging HGGs. Read More

    Use of blood pool agents with steady-state MRI to assess the vascular system.
    J Magn Reson Imaging 2017 Jun 19;45(6):1559-1572. Epub 2017 Apr 19.
    Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
    Over the past two decades there have been significant advances in the use of magnetic resonance imaging (MRI) to assess the vascular system. New imaging sequences and improvements in magnet design have enabled the creation of higher spatial resolution images. MRI is now a viable alternative imaging modality when compared to both invasive angiography and computed tomographic angiography. Read More

    Effect of Intravenous Administration of Contrast Media on Serum Creatinine Levels in Neonates.
    Radiology 2017 08 6;284(2):530-540. Epub 2017 Apr 6.
    From the Departments of Radiology (M.A.B., A.M.W., J.C.E., J.S.M.) and Pediatrics, Division of Nephrology (M.P.), Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, 34th and Civic Center Blvd, Philadelphia, PA 19104; and Hospital Neonatal Intensive Care Unit, Pediatric Medical Group, Huntington Memorial Hospital, Pasadena, Calif (E.L.R.).
    Purpose To assess the effect of intravenous contrast media on renal function in neonates. Materials and Methods Institutional review board approval was obtained with waiver of consent. Electronic health records from January 2011 to April 2013 were reviewed retrospectively. Read More

    Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
    Invest Radiol 2017 06;52(6):317-323
    From the University Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital, University of Bern, Bern, Switzerland.
    For magnetic resonance, the established class of intravenous contrast media is the gadolinium-based contrast agents. In the 3 decades since initial approval, these have proven in general to be very safe for human administration. However, in 2006, a devastating late adverse reaction to administration of the less stable gadolinium-based contrast agents was identified, nephrogenic systemic fibrosis. Read More

    Gadolinium contrast agents - are they really safe?
    J Vasc Access 2017 Mar 21;18(Suppl. 2):1-7. Epub 2017 Mar 21.
    Department of Radiology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague, Prague - Czech Republic.
    Gadolinium-based contrast agents (GBCA) are used worldwide for enhanced MRI examinations, including heart and vessels. Gadolinium is a highly toxic heavy metal. If used in GBCA it must be tightly bound to ligands. Read More

    Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Invest Radiol 2017 06;52(6):324-333
    From the *MR and CT Contrast Media Research, †Research Pathology Berlin, and ‡Medical and Clinical Affairs Radiology, Bayer AG, Berlin; §Special Histopathology, Bayer AG, Elberfeld; ∥Institute of Vegetative Physiology, Charité; ¶Clinical Project Management, Bayer AG, Berlin; and #Central Institute for Engineering, Electronics and Analytics (ZEA-3), Forschungszentrum Juelich GmbH, Juelich, Germany.
    Objectives: Retrospective studies in patients with primary brain tumors or other central nervous system pathologies as well as postmortem studies have suggested that gadolinium (Gd) deposition occurs in the dentate nucleus (DN) and globus pallidus (GP) after multiple administrations of primarily linear Gd-based contrast agents (GBCAs). However, this deposition has not been associated with any adverse effects or histopathological alterations. The aim of this preclinical study was to systematically examine differences between linear and macrocyclic GBCAs in their potential to induce changes in brain and skin histology including Gd distribution in high spatial resolution. Read More

    1 OF 20